This case is the first to show a complete pathological response to BRAF & mitogen-activated protein kinase kinase (MEK) inhibitors.<h4>Case description</h4>-We treated a 22-year-old male with a left groin BRAF<sup>V600E</sup> synovial sarcoma with doxorubicin, Ifosphamide & Sodium 2-Mercaptoethanesulfonate. The gene discussed is WNK2; the disease is synovial sarcoma.